Sign inJoin waitlistJoin the waitlist

Russell Szmulewitz

Director, Genitourinary Oncology Program · University of Chicago Medical Center

Credentials: · · ·

History

Genitourinary Oncology Program · University of Chicago Medical Center
Present

University of Chicago Medical Center
2006–2008
Internal Medicine
NYU Langone Hospitals
2003–2006
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1999–2003

Research

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology · 2019 · 981 citations
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Journal of Clinical Oncology · 2019 · 296 citations
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology · 2022 · 267 citations

Andrew Armstrong
22 papers
Walter Stadler
22 papers
Emmanuel Antonarakis
11 papers
Jeffrey Holzbeierlein
11 papers
NS
Neal Shore
11 papers
Daniel George
9 papers
Daniel Petrylak
9 papers
Peter O'Donnell
9 papers
DD
Daniel Danila
8 papers
GH
Gabriel Haas
8 papers
HS
Howard Scher
8 papers
Mark Ratain
8 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $961K · University of Chicago
1997–2029
SPORE in Prostate Cancer
National Cancer Institute · P50
Project lead · $2.2M · Northwestern University
2015–2021

Clinical trials

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Principal investigator · Not yet recruiting · Phase 4
University of Chicago
2026–2029
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Principal investigator · Recruiting · Phase 2
University of Chicago
2025–2028
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Principal investigator · Terminated · Phase 1
University of Chicago
2023–2024
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Principal investigator · Completed · Phase 1
University of Chicago
2018–2024